MX2024009868A - Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias. - Google Patents

Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.

Info

Publication number
MX2024009868A
MX2024009868A MX2024009868A MX2024009868A MX2024009868A MX 2024009868 A MX2024009868 A MX 2024009868A MX 2024009868 A MX2024009868 A MX 2024009868A MX 2024009868 A MX2024009868 A MX 2024009868A MX 2024009868 A MX2024009868 A MX 2024009868A
Authority
MX
Mexico
Prior art keywords
autoimmune diseases
muteins
interleukin
treatment
agents
Prior art date
Application number
MX2024009868A
Other languages
English (en)
Spanish (es)
Inventor
Jill Yarbrough
Asher Schachter
Mohit Mathur
Susan Sloan
David William Oldach
Nicole Akramoff
Diane Ma
William C Tubbs
Michaela Schultz
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2024009868A publication Critical patent/MX2024009868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2024009868A 2022-02-11 2023-02-10 Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias. MX2024009868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
MX2024009868A true MX2024009868A (es) 2024-08-20

Family

ID=85476118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009868A MX2024009868A (es) 2022-02-11 2023-02-10 Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.

Country Status (10)

Country Link
US (1) US20230390360A1 (https=)
EP (1) EP4475875A1 (https=)
JP (1) JP2025506173A (https=)
KR (1) KR20240148001A (https=)
CN (2) CN119013034A (https=)
AU (1) AU2023219773A1 (https=)
CA (1) CA3243493A1 (https=)
MX (1) MX2024009868A (https=)
TW (1) TW202400218A (https=)
WO (1) WO2023154870A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
CN120346304A (zh) 2025-07-22
KR20240148001A (ko) 2024-10-10
AU2023219773A1 (en) 2024-08-01
US20230390360A1 (en) 2023-12-07
WO2023154870A1 (en) 2023-08-17
CA3243493A1 (en) 2023-08-17
JP2025506173A (ja) 2025-03-07
TW202400218A (zh) 2024-01-01
EP4475875A1 (en) 2024-12-18
CN119013034A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
MY209471A (en) Interleukin-2 agents and uses thereof
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MX2023006599A (es) Metodos de uso de agentes de interleucina-2.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
MX2023008598A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2024009868A (es) Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
PH12022553019A1 (en) Il-17a modulators
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2024001155A (es) Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r.
PH12022500021A1 (en) Il-17a modulators
PH12022552738A1 (en) Compositions comprising nanoparticles, method of making and uses thereof
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
WO2023064278A3 (en) Compositions and methods that inhibit il-23 signaling
MX2024006064A (es) Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.